[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05408728":3,"trial-entities:NCT05408728":79,"trial-summary:NCT05408728":83},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":22,"study_type":23,"primary_purpose":17,"phases":24,"enrollment_info":25,"interventions":28,"primary_outcomes":36,"secondary_outcomes":40,"sex":43,"minimum_age":44,"maximum_age":17,"healthy_volunteers":45,"eligibility_criteria":46,"std_ages":59,"locations":62,"central_contacts":72,"overall_officials":73,"references":77,"see_also_links":78},"NCT05408728","22-001407","Dietary Sugar Absorptive Phenotype for Prediction of Weight Loss Outcome","Dietary Sugar Hyper-absorptive Intestinal Phenotype as a Predictor of Weight Loss Post-bariatric Surgery","ENROLLING_BY_INVITATION","2026-08","2025-09","2025-09-10","2022-07-10","Mayo Clinic","OTHER",false,"This study is trying to determine whether the success of bariatric surgery can be predicted by evaluating the dietary sugar absorptive characteristics in the small intestine and if there is any gene expression change on the dietary sugar absorptive characteristics.",null,[19,20,21],"Obese","Healthy","Bariatric Surgery Candidate",[],"OBSERVATIONAL",[],{"count":26,"type":27},52,"ESTIMATED",[29],{"type":30,"name":31,"description":32,"armGroupLabels":33},"PROCEDURE","Endoscopic biopsy","Upper small intestinal biopsies from patients undergoing BS will be collected during routine standard of care screening EGD and again from the same patients at 1 year during routine standard of care surveillance EGD (esophageal reflux screening\u002Fsurveillance). Biopsy-derived enteroid cultures and tissue samples from pre- and one-year post BS will be examined for expression level of sugar transporters and gluconeogenic enzymes; glucose and fructose absorption",[34,35],"Lean controls naive to Bariatric surgery","Obese patients scheduled for Bariatric surgery",[37],{"measure":38,"timeFrame":39},"Number of obese patients with altered dietary sugar hyper-absorptive phenotype after bariatric surgery","18 months",[41],{"measure":42,"timeFrame":39},"Epigenetic changes measured in the intestinal mucosa of obese patients with dietary sugar hyper-absorptive phenotype after bariatric surgery","ALL","18 Years",true,{"inclusion":47,"exclusion":48,"raw_text":58},[],[49,50,51,52,53,54,55,56,57],"Adults unable to consent, including non-English speakers.","Pregnant women because endoscopy is a risk factor. All patients of childbearing age undergo history as well as urine pregnancy test as a standard of care prior to undergoing endoscopy as the procedure is performed under anesthesia.","Prisoners.","Subjects with preexisting conditions (e.g., bleeding at the time of the procedure, suspected perforation during the standard-of-care procedure) will be excluded from the study at the time of the endoscopy.","Have a contraindication to endoscopy.","A history of surgery on the stomach or small intestine.","Type 1 diabetes (clinical diagnosis and\u002For positive glutamic acid decarboxylase antibodies).","Using weight loss medications.","Active malignancy within the last 5 years.","Inclusion Criteria:\n\n\\- Obese patients (BMI ≥ 30) scheduled for BS undergoing standard of care screening EGD, or lean BS-naïve individuals (BMI ≤ 25) subjected to EGD for routine clinical indications as part of standard care.\n\nExclusion Criteria:\n\n* Adults unable to consent, including non-English speakers.\n* Pregnant women because endoscopy is a risk factor. All patients of childbearing age undergo history as well as urine pregnancy test as a standard of care prior to undergoing endoscopy as the procedure is performed under anesthesia.\n* Prisoners.\n* Subjects with preexisting conditions (e.g., bleeding at the time of the procedure, suspected perforation during the standard-of-care procedure) will be excluded from the study at the time of the endoscopy.\n* Have a contraindication to endoscopy.\n* A history of surgery on the stomach or small intestine.\n* Type 1 diabetes (clinical diagnosis and\u002For positive glutamic acid decarboxylase antibodies).\n* Using weight loss medications.\n* Active malignancy within the last 5 years.",[60,61],"ADULT","OLDER_ADULT",[63],{"facility":64,"city":65,"state":66,"zip":67,"country":68,"geoPoint":69},"Mayo Clinic Florida","Jacksonville","Florida","32224","United States",{"lat":70,"lon":71},30.33218,-81.65565,[],[74],{"name":75,"affiliation":13,"role":76},"Dilhana Badurdeen, MBBS, MD","PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":80,"biomarkers":82},[21,20,81],"Obesity",[],{"nct_id":4,"found":15,"summary":17,"prompt_version":17}]